The global artemisinic acid market size was valued at USD 699.18 million in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 4.24% from 2023 to 2030. This growth can be attributed to the high incidence of malaria, especially in developing and under-developing economies; initiatives by public organizations to raise awareness regarding malaria treatment, and increased research for malaria treatment, are expected to drive the market over the forecast period. The COVID-19 pandemic negatively impacted the demand for malaria treatment initially as treatment preference was given to those that were affected by COVID-19. In March 2020. The WHO urged countries with a high rate of malaria cases in Africa to continue providing malaria services such as detection, treatment, and prevention. This is likely to have boosted the market during the pandemic period. Moreover, the initiatives by these public organizations to eradicate malaria by improving access to treatment are expected to support the market in the post-pandemic period.
Malaria is a life-threatening disease. According to the WHO, in 2021, over half of the total global population was at risk of malaria. The WHO also states that in the same year, over 247 million malaria cases were reported globally. WHO also added that over 619,000 deaths due to malaria were reported in the same year. The high burden of the disease and the significant number of deaths associated with malaria are expected to improve the demand for newer treatment options and create opportunities for artemisinic acid in disease treatment.
Public organizations across the globe have taken initiatives to improve access to effective treatment of malaria to reduce the deaths associated with the disease. For instance, in 2021, WHO, as part of the Malaria Elimination initiative, aimed to provide access to malaria diagnosis, prevention, and treatments as part of universal health coverage. Such initiatives by the public organization to provide treatment at a low cost are expected to improve the demand for treatments such as artemisinic acid and thus support market growth.
In endemic countries around the globe, artemisinin-based combination therapies (ACT) are currently used as the first line of malaria treatment. Artemisinin is made by synthesizing artemisinic acid. The high usage of Artemisinin and the cost-effectiveness of Artemisinin prepared from artemisinic acid is expected to create the demand for the production of artemisinic acid for treating malaria. This is also expected to improve its adoption, especially in endemic countries, and hence support market growth.
The antimalarial tablets segment led the market with the highest revenue share of 80.8% in 2022. The segment is also expected to grow at the fastest rate of 4.3% CAGR. Based on type, the market is segmented into antimalarial injections and antimalarial tablets. Tablets are an oral way of drug administration. Tablets are self-administering and do not require a trained physician for drug administration, which is one of the major reasons for the high acceptance of tablet formulations. Moreover, tablet formulations offer high patient compliance, accurate dosing, control of drug release, and stability. This further improves the demand for antimalarial tablet formulations in the market.
The antimalarial injection segment is anticipated to witness a growth rate of 4.18% over the forecast period. Antimalarial injections are used for severe malaria cases, especially during the time of emergencies. The high bioavailability of injectable formulations leading to the immediate onset of action is the prime factor for its demand in the market. The high number of hospitalizations due to malaria worldwide is expected to boost the segment market growth further.
The Middle East region registered the largest market share of 56.89% in 2022. The regional market growth is expected to grow at the fastest rate of 4.31% across the forecast. Africa is one of the major countries which suffers significantly from malaria. For instance, UNICEF reports that every minute a child under 5 years dies from malaria in Africa. In MEA, public organizations are keen to provide treatment to reduce the number of deaths associated with the disease.
For instance, the WHO in 2021 stated that The African Region of the WHO accounts for a large part of the global malaria burden. In 2021, the region accounted to have 95% of malaria cases and 96% of malaria deaths. The high burden of the disease and the initiative by public organizations to raise awareness regarding the treatment for malaria is benefiting the growth of the regional market.
The Asia Pacific region accounted for the second largest share of 31.83% in 2022. Countries such as India, Pakistan, Indonesia, and others suffer from a high burden of malaria cases in the region. India is known for the world's third-highest malaria burden. The initiatives taken by public organizations in the APAC countries to reduce the burden of malaria and provide proper treatment are expected to boost the market in Asia Pacific. For instance, The government of India developed a National Strategic Plan (NSP, 2017-2022) and National Framework for Malaria Elimination (2016-2030) to eradicate malaria disease by providing treatment at a low cost. Such initiatives are likely to support the market in Asia Pacific in the forecast.
Market players are undertaking various strategic initiatives such as the launch of new product partnerships, collaborations, mergers, and acquisitions aiming to strengthen their product portfolio, and provide a competitive advantage. For instance, Rupus Global Limited, in May 2020, stated that they are about to launch about 50 products in the next 12 months in Africa and UAE for malaria, pain management, and cancer. These products also included artemisinin-based APIs. Such initiatives are likely to support market growth. Some prominent players in the global artemisinic acid market include:
Sanofi
KPC Pharmaceuticals, Inc
Guilin Pharmaceutical Co., Ltd
Calyx Chemicals and Pharmaceuticals Ltd.
Novartis AG
Ipca Laboratories Ltd.
Cipla Inc.
Shin Poong Pharm Co., Ltd.
Rupus Global Limited
AdvacarePharma
Report Attribute |
Details |
Market size value in 2023 |
USD 730.57 million |
Revenue forecast in 2030 |
USD 975.05 million |
Growth rate |
CAGR of 4.24% from 2023 to 2030 |
Base year for estimation |
2022 |
Actual estimates/Historical data |
2018 - 2021 |
Forecast period |
2023 - 2030 |
Quantitative units |
Revenue in USD million, and CAGR from 2023 to 2030 |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered |
Type, region |
Regional scope |
North America; Europe; Asia Pacific, Central & South America, Middle East & Africa |
Country scope |
U.S.; Canada; U.K; Germany; France; Italy; Spain; Denmark; Sweden; Norway; China; India; Japan; South Korea; Thailand; Australia; Pakistan; Indonesia; Vietnam; Colombia; Brazil; Mexico; Argentina; South Africa; UAE; Saudi Arabia; Nigeria; Democratic Republic of Congo; Mali; Uganda; Kenya; Kuwait |
Key companies profiled |
Sanofi; KPC Pharmaceuticals, Inc.; Guilin Pharmaceutical Co., Ltd; Calyx Chemicals and Pharmaceuticals Ltd.; Novartis AG; Ipca Laboratories Ltd.; Cipla Inc.; Shin Poong Pharm Co., Ltd.; Rupus Global Limited; AdvacarePharma |
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global artemisinic acid market report based on type, and region:
Type Outlook (Revenue, USD Million, 2018 - 2030)
Antimalarial Injections
Antimalarial Tablets
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
China
India
Japan
South Korea
Thailand
Australia
Pakistan
Indonesia
Vietnam
Central & South America
Mexico
Argentina
Colombia
Brazil
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
Nigeria
Democratic Republic of Congo
Mali
Uganda
Kenya
b. The global artemisinic acid market size was estimated at USD 699.18 million in 2022 and is expected to reach USD 730.57 million in 2023
b. The global artemisinic acid market is expected to grow at a compound annual growth rate of 4.24% from 2023 to 2030 to reach USD 975.05 million by 2030.
b. Middle East and Africa dominated the artemisinic acid market with a share of 56.89% in 2022. This is attributable to the increasing prevalence of malaria and major awareness initiatives undertaken by governments.
b. Some key players operating in the artemisinic acid market include Sanofi, KPC Pharmaceuticals, Inc, Guilin Pharmaceutical Co., Ltd., Calyx Chemicals and Pharmaceuticals Ltd., Novartis AG, Ipca Laboratories Ltd., and Cipla, Inc.
b. Key factors that are driving the market growth include the increasing prevalence of malaria in developing & developed economies and increasing awareness initiatives undertaken by governments.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."